Chronic Inflammatory Demyelinating Polyneuropathy Market (7MM) Valued at ~USD 1.78 Billion in 2023, Expected to Grow at a Robust CAGR through 2036, Reports DelveInsight

DelveInsight's report titled "Chronic Inflammatory Demyelinating Polyneuropathy Market Insight, Epidemiology, and Market Forecast - 2036" provides a comprehensive understanding of CIDP, including historical and projected epidemiology, along with market trends across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Unlock valuable insights into the CIDP market - explore trends, pipeline developments, and emerging therapies here: https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report
• In June 2025, Sanofi announced that Japan's Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation to riliprubart, a monoclonal antibody targeting activated C1s in the classical complement pathway for CIDP treatment.
• In April 2025, argenx received FDA approval for a prefilled syringe formulation of VYVGART® Hytrulo (efgartigimod alfa with hyaluronidase-qvfc), enabling self-administration for patients with generalized myasthenia gravis and CIDP.
• In March 2025, Immunovant reported topline Phase III results of batoclimab in myasthenia gravis and early findings from its Phase IIb trial in CIDP.
• In 2023, the United States reported the highest number of diagnosed CIDP cases, with approximately 30,230 patients, a figure expected to grow by 2036.
• Among EU4 and the UK, the United Kingdom had the highest diagnosed prevalence with nearly 3,250 cases, followed by Germany with around 3,174 cases, while Spain reported the lowest with approximately 1,691 cases.
• In Japan, around 2,045 diagnosed CIDP cases were recorded in 2023, with projections indicating future growth.
• In 2023, subtype-specific analysis in the U.S. showed approximately 15,417 cases of typical CIDP and 14,813 cases of atypical CIDP.
• Germany reported approximately 2,380 male and 793 female diagnosed CIDP cases in 2023.
• In Japan, age-specific prevalence in 2023 was estimated at 41 (0-19 years), 82 (20-39 years), 798 (40-59 years), 900 (60-79 years), and 225 (80+ years).
• Key companies operating in the CIDP market include CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, and others.
• Promising therapies in development include Riliprubart, Batoclimab (680 mg SC weekly), Efgartigimod PH20 SC, SAR445088 (IV), and others.

Stay ahead in the evolving CIDP market landscape-access in-depth insights and strategic analysis here:
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation in the 7MM
• Diagnosed prevalent cases
• Gender-specific prevalence
• Age-specific prevalence
• Clinical subtype-based prevalence
• Refractory cases

Download the report to explore key epidemiological drivers:
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Marketed Chronic Inflammatory Demyelinating Polyneuropathy Therapies
• HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase): Takeda
HYQVIA is an immunoglobulin-based therapy combined with recombinant hyaluronidase, enabling subcutaneous administration. It provides a convenient alternative to IVIg by allowing larger doses with less frequent administration. The therapy works by modulating immune responses to reduce nerve damage. It received FDA approval in January 2024, followed by approvals in the EU and UK, with Japan approval filed in August 2024.

• VYVGART HYTRULO (Efgartigimod Alfa + Hyaluronidase): argenx
This therapy combines efgartigimod alfa with hyaluronidase to enhance subcutaneous delivery. It works by reducing pathogenic IgG antibodies through FcRn inhibition. Approved by the FDA in June 2024, it also received orphan drug designation for CIDP in 2021 and offers a convenient maintenance treatment option.

• GAMMAGARD LIQUID / KIOVIG (Immune Globulin Infusion 10%): Takeda
A ready-to-use intravenous immunoglobulin (IVIg) therapy derived from human plasma, it helps regulate immune activity, reduce inflammation, and prevent nerve damage. It has demonstrated effectiveness in improving muscle strength and functional outcomes. Approved in the U.S. in January 2024, it also received EU approval earlier for broader patient groups.

Emerging Chronic Inflammatory Demyelinating Polyneuropathy Therapies
• Riliprubart (SAR445088): Sanofi
An investigational IgG4 monoclonal antibody targeting activated C1s, designed to inhibit the complement pathway and reduce inflammation. Currently in Phase III, it focuses on patients resistant to standard therapies.

• Nipocalimab: Janssen Research & Development
A monoclonal antibody targeting FcRn, administered intravenously, aimed at reducing pathogenic IgG levels without broadly suppressing immunity. It is in Phase II/III development for CIDP.

• Batoclimab (HL161): Immunovant / HanAll Pharma / Roivant Sciences
A fully human monoclonal antibody targeting FcRn, designed as a subcutaneous therapy for autoimmune conditions. It reduces IgG levels and is currently in Phase II trials, with results expected to guide further development.

Discover future treatment innovations in CIDP-download the latest report now:
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook
Although classified as a rare disease, CIDP has gained increased recognition in recent years due to advancements in diagnostics, greater awareness among clinicians, and improved understanding of its underlying mechanisms. Treatment strategies focus on controlling inflammation, modulating immune responses, and improving neurological function through pharmacological and supportive approaches.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Landscape
The CIDP treatment approach involves a combination of medications and supportive therapies. Corticosteroids such as prednisone and dexamethasone are often first-line treatments but are associated with long-term side effects like osteoporosis, weight gain, and increased infection risk.
Plasma exchange offers short-term benefits by removing harmful antibodies but is invasive and requires specialized facilities. Intravenous immunoglobulin (IVIg) remains the gold standard due to its effectiveness in long-term disease management, although it is costly, time-intensive, and dependent on plasma supply.

Explore detailed market dynamics and ongoing clinical trials here:
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Inflammatory Demyelinating Polyneuropathy Market Report Scope
• Coverage: 7MM
• Study Period: 2022-2036
• Key Companies: CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, and others
• Key Therapies: Riliprubart, Batoclimab, Efgartigimod PH20, SAR445088, and more
• Market Dynamics: Drivers and barriers
• Additional Insights: Market access, reimbursement, unmet needs, and future outlook

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Methodology
6. Market Overview
7. Disease Background
8. Guidelines
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. 7MM Market Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Perspectives
17. Market Access & Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.